Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for drugs that treat pemphigus vulgaris, an unusual blistering disease of the skin and mucous membranes caused by autoimmunity, is experiencing unique dynamics in line with treatment advancements and increased understanding of the condition. Pemphigus vulgaris treatment landscape is quite different from other diseases as far as drug industry development is concerned. Indeed, targeted biologic therapies designed specifically to fight immunological mechanisms that underlie pemphigus have emerged as a notable trend in this market. Such biologics aim to provide more accurate ways of managing the disease thereby reducing the need for systemic corticosteroids which are the mainstay of its treatment.
The pharmaceutical industry is moving towards personalized medicine where precision medicine approach toward pemphigus vulgaris has been adopted. This move has seen researchers and doctors using genetic and immune-based markers to design treatments that suit individual patients. This shift reflects a larger movement towards precision medicine where strategies are tailored to each patient’s distinct attributes in a bid to maximize response rates while minimizing toxicity levels.
Equally important are novel immunomodulatory agents that have been developed for treating pemphigus vulgaris such as abatacept (CTLA-4) or belimumab (BAFF). These medications act on immune system selectively thus they could attenuate autoimmune reactions causing blistering. Introduction of new immunosuppressive agents demonstrates commitment by stakeholders in finding safer alternatives than traditional drugs hence more suitable therapies for chronic management.
In conclusion, pharmaceutical companies working together with academic research institutions play a significant role in advancing pemphigus vulgaris therapy options. Given its complexity, this epithelial disorder necessitates multidisciplinary approaches which can only be realized through close interaction between academia and industry leading to intricate understanding about pathogenesis of the disease and innovative therapeutic modalities development. It allows industrial-academic partnership to create an enabling environment where scientific breakthroughs are translated into effective treatment methodology.
The pharmaceutical market for pemphigus vulgaris is thereby focused on patient needs, as opposed to the main objective of curing of the disease. This includes improved safety profiles, reduced pill burden and easier administration. In the context of pemphigus vulgaris, there has been a growing tendency among drug manufacturers to consider patients’ concerns in their R&D efforts thus allowing them to enhance quality of life while not limiting themselves only to medical control.
Also, combination therapies have gained prominence in the pemphigus vulgaris market. For example, when different specific pathways are targeted that have links with autoimmunity, some synergy between effects could be expected as well as better outcomes. This trend indicates a broader understanding within industry about pemphigus vulgaries complex nature and comprehensive approaches that need to be taken towards its treatment.
Shortage of Patients available for clinical trials due to that rarity of pemphigus vulgaris is one of the challenges facing pharmaceutical companies in this field. Rare occurrences such as this often necessitate orphan drug designations by regulatory bodies so as stimulate research and development activities in this area since they are usually neglected by other stakeholders. Indeed, an optimal therapeutic strategy for PV is still elusive due to precarious equilibrium between controlling autoimmune responses without causing overt immunosuppression.
Pemphigus Vulgaris Market Highlights:
Global Pemphigus Vulgaris Market Overview
Pemphigus Vulgaris Market Size was valued at USD 1.36 Billion in 2023. The Global Pemphigus Vulgaris industry is projected to grow from USD 1.52 Billion in 2024 to USD 4.83 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.36% during the forecast period (2024 - 2032).
Pemphigus Vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the healthy cells and causes skin problems. Pemphigus Vulgaris affects both men and women, but middle- and old-aged people are more likely to develop this condition.
Pemphigus Vulgaris Market Trends
The key factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, rising bacterial and viral infection, and the growing prevalence of cancer. The side effects associated with the medication and increase in geriatric population are also estimated to drive the market during the forecast period. However, factors such as high cost related to treatment, unfavorable reimbursement situation, and lack of awareness are expected to restrain the market growth
Pemphigus vulgaris is one of the most life-threatening autoimmune skin disorders that occurs due to various reasons such as bacterial infection, increasing pollution, and side effects of some medications. According to the National Organization for Rare Disorders (NORD), 2015, the prevalence of pemphigus was high within the US and Europe affecting approximately 0.7 to 5 people per 1,000,000 each year in the overall population. It was also mentioned that pemphigus foliaceus a form of pemphigus vulgaris has a high prevalence in Africa and some rural areas in the world.
According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US were diagnosed with pemphigus disorder in 2017. The increase in the prevalence of pemphigus vulgaris across the globe is expected to drive market growth during the forecast period from 2024 to 2032.
Pemphigus Vulgaris Market Segment Insights
Pemphigus Vulgaris Treatment Insights
The global pemphigus vulgaris market, by treatment, has been segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy.
Pemphigus Vulgaris Route of Administration Insights
Based on the route of administration, the market has been classified as intravenous, subcutaneous, and oral.
Pemphigus Vulgaris End User Insights
By end user, the global pemphigus vulgaris market has been categorized as hospitals & clinics, specialty dermatology clinics, and research & academic laboratories.
Pemphigus Vulgaris Regional Insights
The global pemphigus vulgaris market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas accounted for the largest market share in 2032 and is estimated to dominate the global pemphigus vulgaris market. The Americas accounts for the largest regional market owing to the increasing prevalence of pemphigus vulgaris, increasing geriatric population, and raising funding for the research & development of skin diseases. According to the National Center for Biotechnology Information 2014, it was predicted that the prevalence of pemphigus vulgaris in the US is in the range of 0.76 to 5 new cases per million every year. Also, according to the International Pemphigus & Pemphigoid Foundation, it was projected that approximately 2,500 people in the US suffered from pemphigus disorder in 2017.
Europe accounted for the second-largest market share in 2017 due to extensive R&D for pemphigus vulgaris, increasing funding, and growing adoption of the technology within the region. Asia-Pacific is expected to contribute to the market growth for pemphigus vulgaris during the forecast period owing to rising therapeutic demand for pemphigus vulgaris and rapidly evolving healthcare sector. On the other hand, the Middle East & Africa is expected to observe slow growth due to low per capita disposable incomes, lack of awareness, and less exposure to healthcare services in this region.
Pemphigus Vulgaris Market Top Key Players
The prominent players in the global pemphigus vulgaris market are
- Almirall, SA
- Argenx SE
- Biogen Inc.
- F. Hoffmann-La Roche
- Syntimmune
- Pfizer Inc.
- Novartis AG
- Sanofi
- Janssen Global Services, LLC
- Principia Biopharma
Some of the key strategies followed by players operating in the global pemphigus vulgaris market were innovation, product development, and acquisition & mergers.
- In December 2017, Almirall SA and Athenex entered into a strategic partnership to develop and commercialize KX2-391 in the US and Europe for the treatment of actinic keratosis.
- In January 2018, Pandion Therapeutics, a start-up led by former executives at Pfizer and Biogen, attracted USD 58 million in financing for the development of a new class of drugs that could tweak the immune system without triggering significant side effects.
- In February 2018, Roche announced that the US Food and Drug Administration (FDA) had accepted the company’s supplemental biologics license application (SBLA) and granted priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Pemphigus Vulgaris Market Segmentation
Pemphigus Vulgaris Treatment Outlook
- Corticosteroids
- Immunosuppressants
- Biological Therapies
- Intravenous Immunoglobulin (IVIG) Therapy
Pemphigus Vulgaris Route of Administration Outlook
- Intravenous
- Subcutaneous
- Oral
Pemphigus Vulgaris End User Outlook
- Hospitals & Clinics
- Specialty Dermatology Clinics
- Research & Academic Laboratories
Pemphigus Vulgaris Regional Outlook
- Americas
- North America
- US
- Canada
- Europe
- Western America
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western America
- Asia-Pacific
- China
- Japan
- Australia
- Republic of Korea
- India
- Rest of Asia-Pacific
- Rest of the world
Available Additional Customizations
- Treatment cost analysis
- Epidemiology data
- Clinical trials data
Intended Audience
- Clinical laboratories
- Pharmaceutical market
- Government organizations
- Research & consulting firms
- Biotechnology companies
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
